Jaguar Health, Inc. (NASDAQ:JAGX)

BRIEF

published on 04/01/2025 at 22:20, 9 months 28 days ago

Jaguar Health Completes Bridge Financing

Private Placement Warrants Jaguar Health Convertible Notes Crofelemer Development
PRESS RELEASE

published on 04/01/2025 at 22:15, 9 months 28 days ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces the closing of a private placement, issuing convertible promissory notes and unregistered warrants to selected investors, with gross proceeds of approximately $3.448 million

Private Placement Warrants Fundraising Jaguar Health Convertible Notes
BRIEF

published on 03/31/2025 at 14:05, 9 months 29 days ago

Jaguar Health Shows 20% Revenue Growth in 2024

Financial Results Jaguar Health Prescription Products FDA Meeting 2024 Revenue Growth
PRESS RELEASE

published on 03/31/2025 at 14:00, 9 months 29 days ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Jaguar Health, Inc. reports a 20% increase in total net revenue for 2024, reaching $11.7 million. Expecting first results in Q2 2025 for crofelemer trials. FDA meeting scheduled for Phase 3 OnTarget trial

Financial Results Jaguar Health Net Revenue FDA Meeting POC Trials
BRIEF

published on 03/28/2025 at 14:05, 10 months 1 day ago

Jaguar Health Highlights Veterinary Support for Canalevia-CA1

FDA Approval Canalevia-CA1 Veterinary Oncology Dog Chemotherapy Non-Antimicrobial Treatment
PRESS RELEASE

published on 03/28/2025 at 14:00, 10 months 1 day ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology

FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea Veterinary Oncology
BRIEF

published on 03/27/2025 at 13:35, 10 months 2 days ago

Jaguar Health Secures FDA Meeting to Discuss Crofelemer Results in Breast Cancer Trial

Crofelemer Jaguar Health Breast Cancer FDA Meeting OnTarget Study
PRESS RELEASE

published on 03/27/2025 at 13:30, 10 months 2 days ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Napo Pharmaceuticals presents statistically significant responder analysis results for crofelemer in breast cancer patients at San Antonio Breast Cancer Symposium and MASCC, FDA Type C Meeting scheduled for 2025

Napo Pharmaceuticals Crofelemer Breast Cancer FDA Meeting Responder Analysis
BRIEF

published on 03/26/2025 at 16:05, 10 months 3 days ago

Jaguar Health to Present at Emerging Growth Conference and Host Investor Webcast

Investor Webcast Jaguar Health Emerging Growth Conference Crofelemer Development Q4 2024 Financials
PRESS RELEASE

published on 03/26/2025 at 16:00, 10 months 3 days ago

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Jaguar Health, Inc. announces virtual presentation and investor webcast dates. Company to file annual report on March 31, 2025. Lisa Conte to discuss upcoming developments

Virtual Presentation Investor Webcast Annual Report Lisa Conte Jaguar Health Inc.

Published on 01/30/2026 at 08:35, 1 hour 14 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 1 hour 49 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 7 hours 34 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 9 hours 49 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 10 hours 49 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE

Published on 01/30/2026 at 09:00, 48 minutes ago

Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 48 minutes ago

Original-Research: q.beyond AG (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 48 minutes ago

Official List Notice
Published on 01/30/2026 at 08:29, 1 hour 19 minutes ago

Notice of Early Redemption
Published on 01/30/2026 at 08:00, 1 hour 48 minutes ago

Ørsted to present its annual report for 2025 on February 6

View all EQS

Published on 01/30/2026 at 08:00, 1 hour 49 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 15 hours 49 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 16 hours 4 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 16 hours 4 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 16 hours 9 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News